Stay updated on Subcutaneous Nivolumab + rHuPH20 Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Nivolumab + rHuPH20 Clinical Trial page.

Latest updates to the Subcutaneous Nivolumab + rHuPH20 Clinical Trial page
- CheckyesterdayChange DetectedThe page’s footer revision label changes from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check8 days agoChange DetectedThe ClinicalTrials.gov page now displays the study record for subcutaneous nivolumab, including study design and outcome measures, participant eligibility, locations, and supporting documents.SummaryDifference86%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.2 to v3.8.0, while the study record page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA sitewide notice announces an NIH website transition and says both “Super Intelligence” and “Artificial Intelligence” may appear during the change.SummaryDifference1%

- Check35 days agoChange DetectedThe footer revision number changed from v3.7.1 to v3.7.2; the study record remains unavailable behind a 403 error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe footer’s site revision indicator changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Subcutaneous Nivolumab + rHuPH20 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Nivolumab + rHuPH20 Clinical Trial page.